Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Anti-IgE therapy is recommended for patients with uncontrolled chronic spontaneous urticaria (CSU) despite treatment with H1-antihistamines. Here, we analyze the effect of ligelizumab, a next-generation anti-IgE antibody, in CSU patients who were treated with locally approved or escalated doses of H1-antihistamines. To read this article in full you will need to make a payment ACAAI Member Login ACAAI Member, full access to the journal is a member benefit.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Ligelizumab, a high affinity humanized monoclonal anti-IgE antibody, was studied in a Phase 2b study (NCT02477332) and its extension study (NCT02649218) in patients with chronic spontaneous urticaria (CSU) inadequately controlled by standard of care including H 1-antihistamines.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Rescue medication (RM) use can be an effective measure of disease control in patients with chronic spontaneous urticaria (CSU). We analyzed the use of rescue medication in patients with CSU during the dose-finding Phase 2b study and the extension study of ligelizumab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
